Metampicillin sodium | 6489-61-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Metampicillin sodium
• 英文别名: sodium;(2S,5R,6R)-3,3-dimethyl-6-[[(2R)-2-(methylideneamino)-2-phenylacetyl]amino]-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
• CAS: 6489-61-8
• 化学式: C17H18N3NaO4S
• 分子量: 383.4
• InChiKey: CRTBAVDGJWEWNJ-GKANRWTBSA-M

物化性质

• 碰撞截面：
  180.4 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  -3.27
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  127
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• METHODS AND COMPOSITIONS FOR TREATING INFECTION
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US20150238473A1

  公开（公告）日：2015-08-27

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• An otorhinological drug delivery device
  申请人：Schering Oy

  公开号：EP1438942A1

  公开（公告）日：2004-07-21

  The invention relates to an otorhinological delivery device comprising at least one pharmaceutically active agent. According to the invention the device comprises a core comprising said at least one pharmaceutically active agent wherein said core is made of an elastomer composition selected from the group consisting of poly(dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units, a siloxane-based elastomer comprising poly(alkylene oxide) groups and mixtures thereof.

  本发明涉及一种包含至少一种药用活性剂的耳鼻喉给药装置。根据本发明，该装置包括一个包含所述至少一种药物活性剂的芯体，其中所述芯体由弹性体组合物制成，该弹性体组合物选自聚（二甲基硅氧烷）、硅氧烷基弹性体（包含连接到硅氧烷单元S原子上的3,3,3-三氟丙基）、硅氧烷基弹性体（包含聚（环氧烷）基团）及其混合物组成的组。
• NOVEL METHODS FOR RAPID DRUG SUSCEPTIBILITY TESTING AND DRUG SCREENS FOR GROWING AND NON-GROWING CELLS OF PROKARYOTIC AND EUKARYOTIC ORIGIN
  申请人：Zhang, Ying

  公开号：EP3321371A1

  公开（公告）日：2018-05-16

  The presently disclosed subject matter provides methods, compositions, and kits for extremely rapid assessment of drug susceptibility of growing as well as non-growing cells of prokaryotic and also eukaryotic origins, without the need for organism growth, which is in contrast to the current growth-dependent methods.This growth-independent new methodology achieves extremely rapid drug susceptibility testing results previously not possible. Methods for rapidly identifying compounds with inhibitory activity against both growing and non-growing cells in real-time continuous manner with previously unachievable efficiency in drug screens using the novel methodology are also provided. Cell cultures are incubated with a drug or test agent and with a staining mixture containing a first fluorescent dye indicative the emission of which is indicative of live cells (e.g. SYBR Green I) and a second fluorescent dye indicative emitting a different color, the emission of which is indicative of dead cells (e.g. Propidium iodide). The ratio of the intensities of the emitted fluorescence of the dyes is indicative of the percentage live and dead cells in the culture.

  与目前依赖生长的方法相比，本公开的主题提供了无需生物体生长即可对原核和真核的生长和非生长细胞的药物敏感性进行极快速评估的方法、组合物和试剂盒，这种不依赖生长的新方法实现了以前无法实现的极快速药物敏感性测试结果。此外，还提供了实时连续地快速鉴定对生长细胞和非生长细胞具有抑制活性的化合物的方法，这种方法在使用新方法进行药物筛选时具有以前无法实现的效率。细胞培养物与药物或测试剂以及染色混合物一起孵育，染色混合物含有第一种荧光染料指示剂，其发射的荧光指示剂可指示活细胞（如 SYBR 绿 I）和第二种发出不同颜色的荧光染料指示剂，其发射的荧光指示剂可指示死细胞（如碘化丙啶）。染料发射荧光强度的比值表示培养液中活细胞和死细胞的百分比。
• Methods and compositions for treating infection
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US10004701B2

  公开（公告）日：2018-06-26

  Provided herein are compositions and methods for treating or preventing infection.

  本文提供了用于治疗或预防感染的组合物和方法。
• Theranostics platform and methods of use
  申请人：Sanford Burnham Prebys Medical Discovery Institute

  公开号：US10161929B2

  公开（公告）日：2018-12-25

  Theranostics platforms for identifying drugs and nutraceuticals for treatment of rare disease are described. The platforms comprise (a) a cell-phenotype image-enhancing instrument; (b) a drug/nutraceutical library; and (c) a computer-implemented system for analyzing a response of an optically-visible rare-disease cell phenotype to a drug or nutraceutical from the drug/nutraceutical library.

  本文描述了用于识别治疗罕见病的药物和营养保健品的血清学平台。这些平台包括：(a) 细胞表型图像增强仪器；(b) 药物/营养保健品库；(c) 计算机实施系统，用于分析光学可视罕见疾病细胞表型对药物/营养保健品库中药物或营养保健品的反应。